268 related articles for article (PubMed ID: 26453583)
21. FcRγ promotes T cell apoptosis in Fas-deficient mice.
Juvet SC; Thomson CW; Kim EY; Joe B; Adeyi O; Zhang L
J Autoimmun; 2013 May; 42():80-93. PubMed ID: 23313147
[TBL] [Abstract][Full Text] [Related]
22. Understanding the Spectrum of Immune Dysregulation Manifestations in Autoimmune Lymphoproliferative Syndrome and Autoimmune Lymphoproliferative Syndrome-like Disorders.
Failing C; Blase JR; Walkovich K
Rheum Dis Clin North Am; 2023 Nov; 49(4):841-860. PubMed ID: 37821199
[TBL] [Abstract][Full Text] [Related]
23. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
24. Lack of IL-17 Receptor A signaling aggravates lymphoproliferation in C57BL/6 lpr mice.
Corneth OBJ; Schaper F; Luk F; Asmawidjaja PS; Mus AMC; Horst G; Heeringa P; Hendriks RW; Westra J; Lubberts E
Sci Rep; 2019 Mar; 9(1):4032. PubMed ID: 30858513
[TBL] [Abstract][Full Text] [Related]
25. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
McInnes IB; Kim HY; Lee SH; Mandel D; Song YW; Connell CA; Luo Z; Brosnan MJ; Zuckerman A; Zwillich SH; Bradley JD
Ann Rheum Dis; 2014 Jan; 73(1):124-31. PubMed ID: 23482473
[TBL] [Abstract][Full Text] [Related]
26. Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS).
Lisco A; Wong CS; Price S; Ye P; Niemela J; Anderson M; Richards E; Manion M; Mystakelis H; Similuk M; Lo B; Stoddard J; Rosenzweig S; Vanpouille C; Rupert A; Maric I; Perez-Diez A; Parenti D; Burbelo PD; Rao VK; Sereti I
Front Immunol; 2019; 10():1193. PubMed ID: 31191551
[TBL] [Abstract][Full Text] [Related]
27. Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha.
Rifkin IR; Channavajhala PL; Kiefer HL; Carmack AJ; Landesman-Bollag E; Beaudette BC; Jersky B; Salant DJ; Ju ST; Marshak-Rothstein A; Seldin DC
J Immunol; 1998 Nov; 161(10):5164-70. PubMed ID: 9820486
[TBL] [Abstract][Full Text] [Related]
28. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
[TBL] [Abstract][Full Text] [Related]
29. Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib.
Okiyama N; Furumoto Y; Villarroel VA; Linton JT; Tsai WL; Gutermuth J; Ghoreschi K; Gadina M; O'Shea JJ; Katz SI
J Invest Dermatol; 2014 Apr; 134(4):992-1000. PubMed ID: 24213371
[TBL] [Abstract][Full Text] [Related]
30. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
[TBL] [Abstract][Full Text] [Related]
31. FcRγ controls the fas-dependent regulatory function of lymphoproliferative double negative T cells.
Juvet SC; Thomson CW; Kim EY; Han M; Zhang L
PLoS One; 2013; 8(6):e65253. PubMed ID: 23762329
[TBL] [Abstract][Full Text] [Related]
32. [A case of autoimmune lymphoproliferactive syndrome and literature review].
Liu L; Hu J; Ma J; Li X; Li F; Li C
Zhonghua Er Ke Za Zhi; 2014 Dec; 52(12):923-6. PubMed ID: 25619350
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
Bobé P; Bonardelle D; Benihoud K; Opolon P; Chelbi-Alix MK
Blood; 2006 Dec; 108(13):3967-75. PubMed ID: 16926289
[TBL] [Abstract][Full Text] [Related]
34. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
Benihoud K; Bonardelle D; Bobé P; Kiger N
Eur J Immunol; 1997 Feb; 27(2):415-20. PubMed ID: 9045912
[TBL] [Abstract][Full Text] [Related]
35. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
Valenzuela F; Korman NJ; Bissonnette R; Bakos N; Tsai TF; Harper MK; Ports WC; Tan H; Tallman A; Valdez H; Gardner AC
Br J Dermatol; 2018 Oct; 179(4):853-862. PubMed ID: 29782642
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
Fleischmann R; Kremer J; Tanaka Y; Gruben D; Kanik K; Koncz T; Krishnaswami S; Wallenstein G; Wilkinson B; Zwillich SH; Keystone E
Int J Rheum Dis; 2016 Dec; 19(12):1216-1225. PubMed ID: 27451980
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Tanaka Y; Maeshima K; Yamaoka K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
[TBL] [Abstract][Full Text] [Related]
38. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
[TBL] [Abstract][Full Text] [Related]
39. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
[TBL] [Abstract][Full Text] [Related]
40. Clinical, immunological, and genetic features in 780 patients with autoimmune lymphoproliferative syndrome (ALPS) and ALPS-like diseases: A systematic review.
Hafezi N; Zaki-Dizaji M; Nirouei M; Asadi G; Sharifinejad N; Jamee M; Erfan Rasouli S; Hamedifar H; Sabzevari A; Chavoshzadeh Z; Yazdani R; Abolhassani H; Aghamohammadi A; Azizi G
Pediatr Allergy Immunol; 2021 Oct; 32(7):1519-1532. PubMed ID: 33963613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
